bioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology Post
28 11월 2023 - 10:00PM
Business Wire
bioAffinity Technologies, Inc. (Nasdaq: BIAF;
BIAFW), a biotechnology company focused on the need for
noninvasive, accurate tests for the detection of early-stage cancer
and lung disease, today announced that David Elzi, Ph.D.,
bioAffinity Technologies Vice President of Research, has been named
to the Membership Committee of the American Society for Cell
Biology (ASCB).
First organized in 1960, ASCB is an international organization
of cell biologists dedicated to advancing scientific discovery,
advocating sound research policies, improving education, promoting
professional development and increasing diversity in the scientific
workforce.
The Membership Committee is responsible for implementing
programs and services to meet the needs of the ASCB’s membership
and support its mission and strategic plan, including recruiting
new members and retaining current members.
“As a member of the Society for more than a decade, I know
firsthand the value of bringing scientists with related research
interests together to share information, work through challenges
and promote the importance of cell biology to government officials,
educators and the general public,” Dr. Elzi said. “I look forward
to working with the Society’s leadership to strengthen ASCB
programs and encourage more participation from the industry/biotech
side of our discipline.”
Dr. Elzi will host a roundtable at Cell Bio 2023, the
collaborative conference of ASCB and the European Molecular Biology
Organization (EMBO), to discuss transferable skills that can make
the transition from academia into the biotech industry easier and
facilitate a successful job search. Aimed at students, post-docs
and research scientists, the roundtable will be held Dec. 3, 2023,
at 1:15 p.m. ET at the Boston Convention Center.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for
noninvasive diagnosis of early-stage cancer and diseases of the
lung and broad-spectrum cancer treatments. The Company’s first
product, CyPath® Lung, is a noninvasive test that has shown high
sensitivity, specificity and accuracy for the detection of
early-stage lung cancer. CyPath® Lung is marketed as a Laboratory
Developed Test (LDT) by Precision Pathology Laboratory Services, a
subsidiary of bioAffinity Technologies. Research and optimization
of the Company’s platform technologies are conducted in its
laboratories at Precision Pathology and The University of Texas at
San Antonio. For more information, visit www.bioaffinitytech.com
and follow us on LinkedIn, Facebook and X.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. These forward-looking
statements are based upon current estimates and assumptions and
include statements regarding working with the American Society for
Cell Biology’s leadership to strengthen ASCB programs and encourage
more participation from the industry/biotech side of bioAffinity’s
discipline. These forward-looking statements are subject to various
risks and uncertainties, many of which are difficult to predict
that could cause actual results to differ materially from current
expectations and assumptions from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from current expectations
include, among others, the ability to strengthen ASCB programs and
encourage more participation and the other factors discussed in the
Company’s Annual Report on Form 10-K for the year ended December
31, 2022, and its subsequent filings with the SEC, including
subsequent periodic reports on Forms 10-Q and 8-K. Such
forward-looking statements are based on facts and conditions as
they exist at the time such statements are made and predictions as
to future facts and conditions. While the Company believes these
forward-looking statements are reasonable, readers of this press
release are cautioned not to place undue reliance on any
forward-looking statements. The information in this release is
provided only as of the date of this release, and the Company does
not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231128477655/en/
bioAffinity Technologies Julie Anne Overton Director of
Communications jao@bioaffinitytech.com
Investor Relations Dave Gentry RedChip Companies Inc.
1-800-RED-CHIP (733-2447) or 407-491-4498 BIAF@redchip.com
bioAffinity Technologies (NASDAQ:BIAFW)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
bioAffinity Technologies (NASDAQ:BIAFW)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024